10 Eli Lilly executives
Ask Eli Lilly's chief scientific and product officer about research partnerships, its head of global manufacturing about capacity or its chief procurement officer about suppliers; the chair and CEO, chief medical officer, three business presidents, the Lilly USA CFO and a former Lilly Oncology president complete the group. Nine are current Lilly executives, useful to biotechs, contract manufacturers and suppliers.
Professionals to explore
Carole Ho
LinkedInExperience: Incoming President Lilly Neuroscience · Eli Lilly and Company
$2,693 per 30-minute call
Incoming President Lilly Neuroscience at Eli Lilly since December 2025, Carole Ho gives Executive Vice President and President, Lilly Neuroscience as the title in Carole's own profile. Chief Medical Officer Head of Development at Denali Therapeutics (2015–2025) and board seats at Beam Therapeutics (since 2018) and Royalty Pharma (since 2025) make Carole a fit for neuroscience development and biotech partnership questions.
Is this you? Claim your profile and get paid for calls.
Daniel Skovronsky
LinkedInExperience: Executive Vice President and Chief Scientific and Product Officer · Eli Lilly and Company
$3,365 per 30-minute call
Daniel Skovronsky has been Executive Vice President and Chief Scientific and Product Officer at Eli Lilly since November 2025 and was Executive Vice President and Chief Scientific Officer from 2018 to 2025. Daniel's summary adds president of Lilly Research Laboratories and oversight of global business development, and Daniel was Founder and Chief Executive Officer of Avid Radiopharmaceuticals, Inc. (2005–2012), a fit for licensing and R&D partnership questions.
Is this you? Claim your profile and get paid for calls.
Dave Ricks
LinkedInExperience: Chair, CEO · Eli Lilly and Company
$10,096 per 30-minute call
Chair, CEO of Eli Lilly and Company since 2017, Dave Ricks also sits on the board of Adobe and the Purdue University Board of Trustees, according to the bio. Earlier Lilly titles include General Manager, Lilly Canada (2005–2008), President and General Manager, Lilly China (2008–2010), President, Lilly USA (2010–2012) and President, Lilly Bio-Medicines (2012–2016), a fit for questions on how the CEO sets priorities across therapeutic areas and countries.
Is this you? Claim your profile and get paid for calls.
David Hyman
LinkedInExperience: Chief Medical Officer, Eli Lilly and Company · Eli Lilly and Company
$2,693 per 30-minute call
David Hyman has been Chief Medical Officer, Eli Lilly and Company since 2023 and Chief Medical Officer at Loxo@Lilly since 2020, directly leading development in the oncology group and working with the CSO, therapeutic-area development leaders and business development, per the summary. At Memorial Sloan Kettering Cancer Center, David was Chief, Early Drug Development (2017–2019) and Associate Member (2018–2020), useful for clinical development and oncology trial questions.
Is this you? Claim your profile and get paid for calls.
Edgardo Hernandez
LinkedInExperience: President, Global Manufacturing · Eli Lilly and Company
$1,010 per 30-minute call
Questions from contract manufacturers and suppliers on API and drug product supply suit Edgardo Hernandez, President, Global Manufacturing at Eli Lilly since 2021 and Sr. Vice President, Drug Product Manufacturing since 2018. Edgardo's Lilly titles also include Site Head, PR06, Small Molecule API (2011–2012), Site Head, Indianapolis API (2013–2016) and Vice President of Manufacturing (2016–2018).
Is this you? Claim your profile and get paid for calls.
Kenneth L. Custer
LinkedInExperience: Executive Vice President and President, Cardiometabolic Health · Eli Lilly and Company
$4,039 per 30-minute call
Diabetes, obesity-related conditions and cardiovascular disease are the work Kenneth L. Custer leads as Executive Vice President and President, Cardiometabolic Health at Eli Lilly (since 2025), per Kenneth's summary. Lilly titles also include Vice President, Portfolio Strategy and Chief of Staff, Lilly Research Labs (2018–2020), Senior Vice President and Head of Corporate Business Development (2020–2023) and President and General Manager of Lilly Canada (2023–2025), a fit for obesity and diabetes partnership questions.
Is this you? Claim your profile and get paid for calls.
Mark Stempel
LinkedInExperience: Sr. Vice President - CFO Lilly USA · Eli Lilly and Company
$2,019 per 30-minute call
US business unit finance is Mark Stempel's ground as Sr. Vice President - CFO Lilly USA (since 2025), and the finance titles before it follow the diabetes business: Associate Vice President, CFO Lilly Diabetes Business Unit (2021–2023), Vice President, CFO Lilly Diabetes & Obesity Business Unit (2023–2024) and Sr. Vice President - CFO Lilly Diabetes & Obesity and Lilly USA (2024–2025). Sr. Director, Corporate Financial Planning and Global Services (2018–2021) adds corporate planning.
Is this you? Claim your profile and get paid for calls.
Patrik Jonsson
LinkedInExperience: Executive Vice President President, Lilly International · Eli Lilly and Company
$4,039 per 30-minute call
An entire career at Lilly, which by Patrik Jonsson's own summary began in 1990 as a sales representative, stands behind the current title Executive Vice President President, Lilly International (since 2025). Patrik's Lilly titles also include Senior Vice President President, Lilly USA and Chief Customer Officer (2020–2021), Executive Vice President President, Lilly Immunology President, Lilly USA, Chief Customer Officer (2021–2024) and Executive Vice President President, Lilly Cardiometabolic Health President, Lilly USA (2024–2025).
Is this you? Claim your profile and get paid for calls.
Sherry Davis
LinkedInExperience: Senior Vice President, Chief Procurement Officer · Eli Lilly and Company
$1,010 per 30-minute call
Procurement and finance meet in Sherry Davis's Lilly career: Senior Vice President, Chief Procurement Officer since 2024, after starting at Lilly in 2006 as a financial consultant with Lilly Research Laboratories, by Sherry's own account. Finance titles include CFO, Lilly USA (2018–2024), Vice President Finance, CFO Lilly USA (2020–2021) and Vice President, CFO, Lilly USA and Immunology (2021–2024), so suppliers asking how procurement and finance work together at a drugmaker fit here.
Is this you? Claim your profile and get paid for calls.
Sue Mahony
LinkedInExperience: President Lilly Oncology · Eli Lilly and Company
$3,365 per 30-minute call
Sue Mahony was President Lilly Oncology from 2011 to 2018, a role Sue's profile says led Lilly's global oncology business, and Senior Vice President Human Resources and Diversity at Lilly from 2009 to 2011. Since 2017 Sue has served as Lead Independent Director, Board Director and Compensation Committee Chair across Axsome Therapeutics, Zymeworks, Assembly Biosciences and Catalent Pharma Solutions, good grounding for oncology business and biotech board questions.
Is this you? Claim your profile and get paid for calls.
Choose the right perspective
For a licensing or research partnership, Daniel Skovronsky, David Hyman and Kenneth L. Custer (a former head of corporate business development) are the closest fit. Manufacturing and supply questions go to Edgardo Hernandez and Sherry Davis, therapeutic-area and market questions to Patrik Jonsson or Carole Ho, and business unit finance to Mark Stempel. Sue Mahony's Lilly roles ended in 2018, so ask about oncology history rather than current plans.
Questions to take into the conversation
- 01When a biotech brings an asset in obesity, neuroscience or oncology, how is the choice made between licensing it, partnering on it or acquiring the company?
- 02How does a drugmaker plan API and drug product capacity ahead of demand for a new medicine, and where do contract manufacturers fit in that plan?
- 03What does a supplier need to show a chief procurement officer at a large drugmaker to become a strategic partner rather than one of many vendors?
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.